Ulcerated breast cancer with single brain metastasis: A combined surgical approach. Clinical presentation at one year follow up – A case report

Santori, Francesca; Vanni, Gianluca; Buonomo, Oreste Claudio; Majo, Adriano De; Rho, Maurizio; Granai, Alessandra Vittoria; Pellicciaro, Marco; Cotesta, Maria; Assogna, Massimo; D’Angelillo, Rolando Maria; Materazzo, Marco

doi:10.1016/j.ijscr.2020.06.074

Cited by 2 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor progression is a multistep complex cascade (19) which requires evasion from the host's immunosurveillance mechanisms (27). Immunoediting could eventually result in short or long term distant relapse (28,29). In order to reduce the treatment immunological impairment, several medical and surgical strategies have been implemented in clinical practice (15,16,(39)(40)(41).…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies demonstrate that these immune cells are indeed mounting an antitumor response which could eventually determine cancer immmunosurveillance (23)(24)(25)(26). That said, tumor progression is a multistep complex cascade (19), which requires evasion from the host's immunosurveillance mechanisms (27) and immunoediting eventually resulting in short or long term distant relapse (28)(29)(30). Due to the novelty of the COVID-19 outbreak, there is a lack of evidence regarding the complex relationship between altered immunological status and the COVID-19 disease in oncological patients (13,14,28,29).…”

mentioning

confidence: 99%

“…That said, tumor progression is a multistep complex cascade (19), which requires evasion from the host's immunosurveillance mechanisms (27) and immunoediting eventually resulting in short or long term distant relapse (28)(29)(30). Due to the novelty of the COVID-19 outbreak, there is a lack of evidence regarding the complex relationship between altered immunological status and the COVID-19 disease in oncological patients (13,14,28,29). Theoretically, oncological preexistent immunosuppression could harm or benefit different subsets of COVID-19 patients, reducing the cytokine storm or further complicating the disease course (13,14).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Lymphocytes, Interleukin 6 and D-dimer Cannot Predict Clinical Outcome in Coronavirus Cancer Patients: LyNC1.20 Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background/Aim: Knowledge of Coronavirus 19 (COVID19) pathogenetic mechanisms is necessary to provide new treatment strategies. This study aims to assess how oncological disease impacts on the clinical course of COVID-19 patients. Patients and Methods: From 1 st March to 30 th April 2020, 96 COVID-19 patients were classified according to clinical outcome as severe (n=67) and moderate (n=29). Demographic data, medical history, admission lymphocytes, procalcitonin (PCT), were collected. Results: A statistically significant association was found between hypertension (p=0.007) and three or more comorbidities with severe outcomes (p=0.034). No statistical differences were found between the severe and moderate groups with regards to the rate of patients with past oncological history. However, no patient allocated in the moderate group had received oncological treatment within 12 months. Higher values of CRP, IL-6, D-Dimer and lower values of lymphocytes were reported in the severe group (p=0.0007, p=0.00386, p=0.041, and p=0.007, respectively). Using binary logistic regression, higher values of CRP (OR=8.861; p=0.012) and PCT were associated with a higher risk of severe outcome (OR=21.075; p=0.008). Within the oncological population, D-Dimer and IL-6 did not confirm their prognostic significance as in the general population (p>0.05). Conclusion: Specific prognostic factors for oncological patients should be designed for COVID-19 clinical practice.The Coronavirus-19 (COVID-19) pandemic represents a global challenge due to the rapid spread and poor prognosis, with a fatality rate of 6.2% and more than 5 million people infected worldwide (1). COVID-19 has strongly impacted all medical science fields and several physicians are currently reorganizing their clinical practice in order to provide the best treatment and reduce the risk of cross contamination (2-4). Based on the most recent flu pandemic, the Center for Infectious Disease Research and Policy (CIDRAP) calculated that this outbreak will likely last up to 24 months (1). In 307 This article is freely accessible online.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Lymphocytes, Interleukin 6 and D-dimer Cannot Predict Clinical Outcome in Coronavirus Cancer Patients: LyNC1.20 Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…It also shows the effectiveness of primary tumor surgery for a better prognosis at an early stage under specific clinical conditions. On the other hand, multiple surgical approaches provide a better opportunity to reduce the anesthesiologic conditions and unnecessary surgical trauma [ 70 ].…”

Section: Surgical Approachesmentioning

confidence: 99%

An Insight into Molecular Targets of Breast Cancer Brain Metastasis

Kaleem¹,

Dalhat

Azmi³

et al. 2022

IJMS

View full text Add to dashboard Cite

Brain metastasis is one of the major reasons of death in breast cancer (BC) patients, significantly affecting the quality of life, physical activity, and interdependence on several individuals. There is no clear evidence in scientific literature that depicts an exact mechanism relating to brain metastasis in BC patients. The tendency to develop breast cancer brain metastases (BCBMs) differs by the BC subtype, varying from almost half with triple-negative breast cancer (TNBC) (HER2− ER− PR−), one-third with HER2+ (human epidermal growth factor receptor 2-positive, and around one-tenth with luminal subclass (ER+ (estrogen positive) or PR+ (progesterone positive)) breast cancer. This review focuses on the molecular pathways as possible therapeutic targets of BCBMs and their potent drugs under different stages of clinical trial. In view of increased numbers of clinical trials and systemic studies, the scientific community is hopeful of unraveling the underlying mechanisms of BCBMs that will help in designing an effective treatment regimen with multiple molecular targets.

show abstract

Ulcerated breast cancer with single brain metastasis: A combined surgical approach. Clinical presentation at one year follow up – A case report

Cited by 2 publications

References 20 publications

Lymphocytes, Interleukin 6 and D-dimer Cannot Predict Clinical Outcome in Coronavirus Cancer Patients: LyNC1.20 Study

Lymphocytes, Interleukin 6 and D-dimer Cannot Predict Clinical Outcome in Coronavirus Cancer Patients: LyNC1.20 Study

An Insight into Molecular Targets of Breast Cancer Brain Metastasis

Contact Info

Product

Resources

About